Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-26T07:04:49.108Z Has data issue: false hasContentIssue false

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

Published online by Cambridge University Press:  09 July 2009

I. Falloon
Affiliation:
St John's Hospital, Stone, Aylesbury and the Institute of Psychiatry, London
D. C. Watt
Affiliation:
St John's Hospital, Stone, Aylesbury and the Institute of Psychiatry, London
Michael Shepherd*
Affiliation:
St John's Hospital, Stone, Aylesbury and the Institute of Psychiatry, London
*
1Address for correspondence: Professor Michael Shepherd, Institute of Psychiatry, De Crespigny Park, London SE5 8AF.

Synopsis

Evidence from a controlled, comparative trial indicates that oral pimozide is clinically at least as effective as depot injections of fluphenazine decanoate in the continuation therapy of a group of schizophrenic patients discharged from hospital. The administration of pimozide was associated with fewer unwanted effects. The implications of the findings are discussed.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1978

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

de Alarćon, R. & Carney, M. W. P. (1969). Severe depressive mood changes following slow-release intramuscular fluphenazine injection. British Medical Journal iii, 564567.CrossRefGoogle Scholar
Andrews, W. N. (1973). Long-acting tranquillizers and the amotivational syndrome in the treatment of schizophrenia. In Community Management of the Schizophrenic in Chemical Remission (ed. King, M. H.), pp. 14. Excerpta Medica: Amsterdam.Google Scholar
Ayd, F. J. Jr (1974). Side effects of depot fluphenazines. Comprehensive Psychiatry 15, 277284.CrossRefGoogle ScholarPubMed
Blackwell, B. (1976). Treatment adherence. British Journal of Psychiatry 129, 513531.CrossRefGoogle ScholarPubMed
Claveria, L. E., Teychenne, P. F. & Calne, D. B. (1975). Tardive dyskinesia treated with pimozide. Journal of the Neurological Sciences 24, 393.CrossRefGoogle ScholarPubMed
Crawford, R. & Forrest, A. (1974). Controlled trial of depot fluphenazine in outpatient schizophrenics. British Journal of Psychiatry 124, 385391.CrossRefGoogle Scholar
Crumpton, N. (1968). The role of drugs in maintaining patients in the community. In The Treatment of Mental Disorders in the Community (ed. Daniel, G. R. and Freeman, H. L.), pp. 1524. Baillière: London.Google Scholar
Denham, J. & Adamson, L. (1971). The contribution of fluphenazine enanthate and decanoate in the prevention of re-admission of schizophrenic patients. Acta Psychiatrica Scandinavica 47, 420430.CrossRefGoogle Scholar
Falloon, I., Watt, D. C. & Shepherd, M. (1978). The social outcome of schizophrenic patients in a trial of continuation therapy. Psychological Medicine 8 (in the press).CrossRefGoogle Scholar
Hirsch, S. R., Gaind, R., Rohde, P. D., Stevens, B. C. & Wing, J. K. (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. British Medical Journal i, 633637.CrossRefGoogle Scholar
Hunter, R., Earl, C. J. & Thornicroft, S. (1964). An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proceedings of the Royal Society of Medicine 57, 758763.CrossRefGoogle ScholarPubMed
Imlah, N. W. & Murphy, K. P. (1970). Preliminary followup study of patients attending a Modecate Clinic. In Symposium on Long-Acting Phenothiazines (ed. Cole, J. O.), p. 19. Excerpta Medica: Amsterdam.Google Scholar
Johnson, D. A. W. (1975). Observations on the dose regime of fluphenazine decanoate in maintenance therapy of schizophrenia. British Journal of Psychiatry 126, 457461.CrossRefGoogle Scholar
Johnson, D. A. W. & Freeman, H. (1972). Long-acting tranquillizers. The Practitioner 208, 395400.Google ScholarPubMed
Jones, I. H. & Letemendia, F. J. J. (1966). Medication marker. British Medical Journal ii, 948949.CrossRefGoogle Scholar
Kazamatsuri, H., Chien, C.-P. & Cole, J. O. (1972). Therapeutic approaches to tardive dyskinesia. Archives of General Psychiatry 27, 491499.CrossRefGoogle ScholarPubMed
Leff, J. P. (1973). Influence of selection of patients on results of clinical trials. British Medical Journal iv, 156158.CrossRefGoogle Scholar
Leff, J. P. (1976). Assessment of psychiatric and social state. British Journal of Clinical Pharmacology, Supplement, 385390.Google Scholar
Leff, J. P. & Wing, J. K. (1971). Trial of maintenance therapy in schizophrenia. British Medical Journal iii, 599604.CrossRefGoogle Scholar
Marshall, W. K. (1971). Pimozide (Orap): a multicentre study. Clinical Trials Journal 8, Supplement II, 4954.Google Scholar
McGlashan, T. H. & Carpenter, W. T. (1976). Postpsychotic depression in schizophrenia. Archives of General Psychiatry 33, 321329.CrossRefGoogle ScholarPubMed
Mayer-Gross, W. (1920). Über die Stellungsnahme auf abgelaufenen akuten Psychose. Zentralblatt für die gesamte Neurologie und Psychiatrie 60, 160212.CrossRefGoogle Scholar
Pinder, R. M., Brogden, R. N., Sawyer, T. M., Speight, R. S. & Avery, G. S. (1976). Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 12, 140.CrossRefGoogle ScholarPubMed
Rifkin, A., Quitkin, F., Rabiner, C. J. & Klein, D. F. (1977). Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics. Archives of General Psychiatry 34, 4347.CrossRefGoogle ScholarPubMed
Schneider, K. (1959). Clinical Psychopathology (trans. Hamilton, M. W.). Grune and Stratton: New York.Google Scholar
Sheldrick, C., Jablensky, A., Sartorius, N. & Shepherd, M. (1977). Schizophrenia succeeded by affective disorder: a catamnestic and statistical enquiry. Psychological Medicine 7, 619624.CrossRefGoogle ScholarPubMed
Stevens, B. C. (1972). Dependence of schizophrenic patients on elderly relatives. Psychological Medicine 2, 1732.CrossRefGoogle ScholarPubMed
Van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry 31, 6772.CrossRefGoogle ScholarPubMed
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974). The Measurement and Classification of Psychiatric Symptoms. Cambridge University Press: London.Google Scholar